ASTX029

ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC50: 2.7 nM) . ASTX029 has anti-cancer activity[1][2].

Product Specifications

CAS Number

[2095719-92-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; ERK

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/astx029.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

ClC(C(C1=CC2=C(CN([C@H](C)C(N[C@H](CO)C3=CC(F)=CC(OC)=C3)=O)C2=O)C=C1)=N4)=CN=C4NC5CCOCC5

Molecular Formula

C29H31ClFN5O5

Molecular Weight

584.04

Precautions

H302, H315, H319, H335

References & Citations

[1]Michael Reader, et al. 6-pyrimidin-isoindole derivative as erk1/2 inhibitor. WO2018193410A1.|[2]Munck JM, et al. ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Mol Cancer Ther. 2021 Oct;20 (10) :1757-1768.